Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review - Wikidata - wikimedia - TriplyDB

Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review

Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review

http://www.wikidata.org/entity/Q26851448

about

Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study.Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.What is the benefit of the biomedical and behavioral interventions in preventing HIV transmission?Are you PEPped and PrEPped for travel? Risk mitigation of HIV infection for travelers.Antiretroviral treatment for HIV infection: Swedish recommendations 2016.PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.World Health Organization Guidelines on Postexposure Prophylaxis for HIV: Recommendations for a Public Health Approach.HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).Adherence to HIV Postexposure Prophylaxis in a Major Hospital in Northwestern Nigeria.Progress in HIV vaccine development

P2860

Q33592530-F9BA9400-CDCA-4A8B-AB95-12FEF4FAEE50 Q36205915-D8ED3822-A2E5-44CD-A99D-89D7C1BA12D5 Q38656811-42F2BFC1-F9D3-4EF4-ABBA-078000C5F48C Q40051935-E1005333-7849-418D-9C94-A4FE2E18FE43 Q40470257-6F458B43-4684-4816-B52F-A2BD0C2FD200 Q40679634-E78194AD-201E-4979-B4A5-BD04B9EDAD53 Q41233149-2AA8D14B-D016-49DF-814D-04224054D060 Q47303141-AFF47DD8-1AD2-4716-B776-550C59EE32F4 Q47830535-FB962AAE-973E-4B4E-913E-AB1C7FE0EDD2 Q50241527-C6055409-3202-4519-878B-EC2652A4A197 Q56970600-F61D7448-6AB4-428A-A449-2B8A469C3956

P2860

Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review

http://www.wikidata.org/entity/Q26851448

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Choice of antiretroviral drugs ...... olescents: a systematic review

@ast

Choice of antiretroviral drugs ...... olescents: a systematic review

@en

Choice of antiretroviral drugs ...... olescents: a systematic review

@nl

type

label

Choice of antiretroviral drugs ...... olescents: a systematic review

@ast

Choice of antiretroviral drugs ...... olescents: a systematic review

@en

Choice of antiretroviral drugs ...... olescents: a systematic review

@nl

prefLabel

Choice of antiretroviral drugs ...... olescents: a systematic review

@ast

Choice of antiretroviral drugs ...... olescents: a systematic review

@en

Choice of antiretroviral drugs ...... olescents: a systematic review

@nl

P1433

Q26851448-A06A85FE-FAA7-41F7-A294-0B1B46717D67

P1476

Q26851448-2644D0A8-2F39-41B4-90A6-7686203F998B

P2093

Q26851448-011AED0F-DB0D-4971-B9CE-4F5979D8401F

Q26851448-0485383B-7A48-4DB8-B6D5-0D4B0A9763F1

Q26851448-0DEA4461-A280-46F1-BCA3-6ED22AB7B31C

Q26851448-320C0B2A-1283-457F-822E-023D9E63CD61

Q26851448-5AD27925-49B9-4760-AFE6-ECBA8F01AA8A

Q26851448-73010E3B-8051-4DAB-A97C-ABB576E61030

Q26851448-818CC4EB-97D7-4386-983D-781034541A67

Q26851448-9776D892-C969-4DDB-936E-1C526BB9FC2F

Q26851448-9DABFA54-2384-4BC4-9447-D44C53817595

Q26851448-EA45E65F-815B-4DE4-B660-72C7331D1CB4

P2860

Q26851448-08B1E894-1899-4AD5-B838-993C1C611B2A

Q26851448-0EC1DE5E-F769-4589-B003-B83078FF819F

Q26851448-11F76C46-3F41-41A4-BE28-60571010698D

Q26851448-2D1850BC-28FE-479D-8B1C-8995B6334565

Q26851448-2DB9BF2C-4E7F-4056-8D6E-5FAE99D68A0E

Q26851448-302A9F75-96B4-4328-A3E4-EEE38161311F

Q26851448-3515C9C0-65EC-43F5-AE48-A0022659C132

Q26851448-3B0494ED-A7B4-4107-BB6D-4269F8624908

Q26851448-3E2AD30A-890E-48FC-94E2-439A35FB3D3B

Q26851448-3EC82D6A-3A8A-4FDE-AA76-94EC0673E162

P304

Q26851448-D46441B8-53BE-4F0A-9276-C01A18517779

P31

Q26851448-89E321F7-BF05-4AFB-BDA9-A8E3E0427F92

Q26851448-D2942076-F3B6-45DD-BF28-01B2B42A9DC7

Q26851448-e31c7b26-1661-4af4-9dbc-96d7b2f1e67c

P356

Q26851448-CD418AE8-93C0-4849-B10B-E467D15CAFE8

P407

Q26851448-C00A1B4E-C923-4121-897B-D22417628918

P478

Q26851448-070C2363-9BA6-4CCD-8B8F-1B398DDD1E30

P577

Q26851448-9B517F58-8F89-4B90-A818-F30E5F5F6AD1

P5875

Q26851448-EA6B6FE5-06EC-4677-A01D-925FDF70A8D5

P698

Q26851448-CE58D28D-864F-4E57-AB3E-CBCBC9A88C9F

P921

Q26851448-7FA8D5AC-C989-4816-8326-87B8FA091483

Q26851448-9B961014-95E9-4499-B1AD-E834C75D72AE

P356

P1433

Clinical Infectious Diseases

P1476

Choice of antiretroviral drugs ...... olescents: a systematic review

@en

P2093

A. Calmy

http://www.w3.org/2001/XMLSchema#string

C. Irvine

http://www.w3.org/2001/XMLSchema#string

C. Rapparini

http://www.w3.org/2001/XMLSchema#string

K. H. Mayer

http://www.w3.org/2001/XMLSchema#string

M. Doherty

http://www.w3.org/2001/XMLSchema#string

M. Vitoria

http://www.w3.org/2001/XMLSchema#string

N. Ford

http://www.w3.org/2001/XMLSchema#string

O. Ajose

http://www.w3.org/2001/XMLSchema#string

R. L. Beanland

http://www.w3.org/2001/XMLSchema#string

Z. Shubber

http://www.w3.org/2001/XMLSchema#string

P2860

Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis

What is "quality of evidence" and why is it important to clinicians?

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Transformations Related to the Angular and the Square Root

Preexposure prophylaxis for HIV infection among African women

Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.

Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry.

Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic.

A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV

P304

S170-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P356

10.1093/CID/CIV092

http://www.w3.org/2001/XMLSchema#string

P407

P478

60 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276360087

http://www.w3.org/2001/XMLSchema#string

P698

25972499

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug